Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
Annamaria Colao(Federico II University Hospital), Pamela U. Freda(Columbia University), Mary N. Sheppard(St George's, University of London), A. J. van der Lely(Erasmus MC), Feng Gu(Xuzhou Medical College), Yixin Chen, Karina Hermosillo Reséndiz, Maria Fleseriu(Oregon Health & Science University), Mônica R. Gadelha(Universidade Federal do Rio de Janeiro), Chiung‐Chyi Shen(Taichung Veterans General Hospital), Marcello D. Bronstein(Universidade de São Paulo), Matthieu Ruffin(Novartis (Switzerland)), Andrew J. Farrall(University of Edinburgh)
Cited by 394
Related Papers
Current State of knowledge on Takotsubo Syndrome: A Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2015|1.2k
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
|Circulation|2005|978
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
|The Journal of Clinical Endocrinology & Metabolism|2016|921
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
|Clinical Endocrinology|2006|830